Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years
Status:
Completed
Trial end date:
2019-07-02
Target enrollment:
Participant gender:
Summary
Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the
world map of HCV. Results in adults are promising. FDA approved only two drugs in the
pediatric age group 12 to 17 years. Younger children are still on the wait list for
treatment. The current study aimed to treat children aged between 3 and 12 years with half
the adult dose of Sofosbuvir/Ledipasvir combination (Heterosofir).